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Background: Human mitochondrial peptide deformylase (PDF) has been proposed as a novel cancer therapeutic
target. However, very little is known about its expression and regulation in human tissues. The purpose of this study
was to characterize the expression pattern of PDF in cancerous tissues and to identify mechanisms that regulate its
expression.
Methods: The mRNA expression levels of PDF and methionine aminopeptidase 1D (MAP1D), an enzyme involved
in a related pathway with PDF, were determined using tissue panels containing cDNA from patients with various
types of cancer (breast, colon, kidney, liver, lung, ovarian, prostate, or thyroid) and human cell lines. Protein levels of
PDF were also determined in 2 colon cancer patients via western blotting. Colon cancer cells were treated with
inhibitors of ERK, Akt, and mTOR signaling pathways and the resulting effects on PDF and MAP1D mRNA levels
were determined by qPCR for colon and lung cancer cell lines. Finally, the effects of a PDF inhibitor, actinonin, on
the proliferation of breast, colon, and prostate cell lines were determined using the CyQUANT assay.
Results: PDF and MAP1D mRNA levels were elevated in cancer cell lines compared to non-cancer lines. PDF mRNA
levels were significantly increased in breast, colon, and lung cancer samples while MAP1D mRNA levels were
increased in just colon cancers. The expression of PDF and MAP1D varied with stage in these cancers. Further, PDF
protein expression was elevated in colon cancer tissue samples. Inhibition of the MEK/ERK, but not PI3K or mTOR,
pathway reduced the expression of PDF and MAP1D in both colon and lung cancer cell lines. Further, inhibition of
PDF with actinonin resulted in greater reduction of breast, colon, and prostate cancer cell proliferation than
non-cancer cell lines.
Conclusions: This is the first report showing that PDF is over-expressed in breast, colon, and lung cancers, and the
first evidence that the MEK/ERK pathway plays a role in regulating the expression of PDF and MAP1D. The
over-expression of PDF in several cancers and the inhibition of cancer cell growth by a PDF inhibitor suggest this
enzyme may act as an oncogene to promote cancer cell proliferation.Background
In prokaryotic organisms, the N-terminal methionine ex-
cision (NME) pathway is indispensible for proper protein
functioning. This pathway involves two enzymes; peptide
deformylase (PDF) which removes the formyl group from
the initial methionine in nascent peptides, and methionine
aminopeptidase (MAP) which subsequently removes the
initial methionine [1]. Until recently, PDF was thought to
exist only in prokaryotic organisms and hence has been* Correspondence: Katie.Reindl@ndsu.edu
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distribution, and reproduction in any mediumthe target of antimicrobial agents [2-5]. However, the
recent discovery of PDF and a MAP isoform in the
mitochondria of eukaryotes raises questions regarding
their role in human cells [6-8].
Studies show that human PDF (HsPDF) can cleave the
formyl group from an initiator methionine, but with
reduced kinetics compared to the prokaryotic versions
of the enzyme [2,8,9]. However, many of the respiratory
Complex I peptides generated from mtDNA, putative
substrates for PDF and MAP1D, retain their formylated
initiator methionine [10]. In contrast, a recent report
suggests that inhibition of PDF with actinonin results in
reduced aerobic respiratory capacity by influencing the
expression of proteins derived from the mtDNA [11].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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in humans, it is likely PDF and MAP1D have alternative
functions. Indeed, RNA interference of MAP1D altered
anchorage-dependent growth of colon cancer cells [12]
and inhibition of PDF with actinonin and numerous
analogs decreased proliferation of many cancer cells while
having minimal effects on non-cancer cell lines [13]. Fur-
ther, PDF inhibitors resulted in a reduced tumor volume in
a mouse xenograft model using HL-60 [14]. These results
have lead to recent studies focused on the design of inhibi-
tors to target PDF in cancer [14-16].
Despite these advances, little is known about the ex-
pression and regulation of the NME enzymes in cancers.
MAP1D is over-expressed in colon cancer [12], but no
study has reported the expression of PDF in cancerous
compared to normal tissues. Further, no study has
described a mechanism that regulates human PDF or
MAP1D expression. Therefore, the purpose of this study
was to identify the expression profiles of PDF and MAP1D
in human cancers compared to normal tissues and to
identify a signaling pathway involved in regulating their
expression. Given the role of human PDF and MAP1D in
cancer cell growth and adhesion, we hypothesized that
these proteins would be up-regulated in cancer cells and
tissues compared to normal and their expression would be
modulated by growth-regulatory pathways. In this paper,
we report that PDF is elevated in breast, colon, and lung
cancer tissues and MAP1D is elevated in colon cancer
tissue samples compared to non-cancer controls. We also
show that PDF and MAP1D mRNA expression is down-
regulated when MEK/ERK signaling is disrupted.
Methods
Cell culture
All cell lines, unless otherwise noted, were obtained
from ATCC (Manassas, VA) and cultured at 37°C with
5% carbon dioxide. Hs578Bst normal breast cells were
maintained in Hybri-Care Medium (ATCC) supplemented
with 1.5 g/L sodium bicarbonate (Sigma; St. Louis, MO),
30 ng/ml mouse EGF (BD Biosciences; San Jose, CA),
and 10% fetal bovine serum (FBS; Atlanta Biologicals;
Lawrenceville, GA). Hs578T breast cancer cells were
cultured in Dulbecco's Modified Eagle's Medium (DMEM;
Thermo Scientific; Waltham, MA) supplemented with
0.01 mg/ml bovine insulin (Sigma) and 10% FBS. CCD-
18Co normal colon cells were maintained in Eagle's
Minimum Essential Medium (EMEM; ATCC) supplemented
with 10% FBS. HT-29 colon cancer cells were cultured in
McCoy’s 5a (Thermo Scientific) medium supplemented
with 10% FBS. Hs888Lu normal lung fibroblasts and A549
lung cancer cells were cultured in DMEM plus 10% FBS.
PrEC normal prostate epithelial cells were obtained from
Cambrex Corporation (East Rutherford, NJ) and propa-
gated in PrEGM media with Bulletkit growth supplements(Cambrex). PC-3 cells were grown in Ham’s F-12 K
medium supplemented with 10% FBS.
Human tissue samples and cDNA
TissueScan Cancer qPCR Arrays containing cDNA from
normal and cancer tissue samples were purchased from
Origene (Rockville, MA). The cDNA panels (cancer survey
panel CSRT101, breast cancer panel BCRT101, matched
colon cancer panel HCRT103, and matched lung cancer
panel HLRT104), each had 48–96 samples per microplate.
Equal loading of cDNA was verified by the manufacturer.
Additionally, matched normal and colon cancer samples
were obtained from two patients at the Veteran’s Affairs
(VA) Hospital in Fargo, ND. This research was approved by
the University of South Dakota and the North Dakota State
University Institutional Review Board and performed
according to the ethical guidelines imposed by these boards.
Informed consent was obtained from each participant.
Total RNA was isolated from human cell lines using the
Fisher SurePrep Kit (Waltham, MA) and from human
tissue samples using TRI Reagent (Molecular Research
Center; Cincinnati, OH) as per the manufacturer’s sug-
gestions. 100 ng of total RNA were reverse transcribed
into cDNA using the qScript cDNA synthesis kit (Quanta
Biosciences; Gaithersburg, MD).
Signal transduction pathway inhibitors
HT-29 colon cancer cells were seeded into a 6 well plate
at 1.5 million cells per well and incubated overnight.
The next day, the cells were treated for 5 hours with
10 μM U0126, 10 μM LY294002, or 10 μM rapamycin
(all from Cell Signaling). Total RNA or total protein was
collected from the cells for further analysis.
QPCR
Primers against human PDF and MAP1D were designed
using Primer Express software (Applied Biosystems;
Carlsbad, CA) and synthesized by Integrated DNA
Technologies (Coralville, IA). Primer sequences were as
follows; PDF forward AGGCGCTGTGTCGGGAGTGC,
PDF reverse TCTCGCAGCCCTCGGGAAAG, MAP1D
forward TATAGTTTTGCCGGCTGCAGT, MAP1D re-
verse ATGTGCTTAGGAACCGGATGA, β-actin for-
ward CAGCCATGTACGTTGCTATCCAGG, β-actin
reverse AGGTCCAGACGCAGGATGGCATG. Steady-
state mRNA levels of PDF or MAP1D were determined
for all cDNAs by real-time PCR using PerfeCTa SYBR
Green FastMix (Quanta Biosciences). The cycling parame-
ters were 95°C for 10 min followed by 40 cycles of 95°C
for 30 sec and 60°C for 1 min and a dissociation program
that included 95°C for 1 min, 55°C for 30 sec, and 95°C
for 30 sec ramping up at 0.2°C/sec. One distinct peak
was observed for the primer sets. For the cell lines,
qPCR standards were prepared using human PDF and
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(Catalog numbers IHS1380-97652083 and MHS4426-
99238965, Huntsville, AL). The 1010 molecules/μL standard
was serially diluted to 102 molecules/μL. The standards
were run alongside the cDNA from the human cell lines in
order to approximate the copy number of PDF or MAP1D
in these cells. For the cDNA panels, fold-change in
mRNA expression was calculated by comparing normalized
threshold cycle numbers (CT) in the cancerous tissue
compared to the normal tissues. The cell experiments
were performed in triplicate.
SDS-PAGE and western blotting
Cell pellets or human tissue samples from the VA Hospital
were lysed using an SDS lysis buffer (Cell Signaling
Technologies, Danvers, MA) containing protease and
phosphatases inhibitors (Roche; Indianapolis, IN). Samples
were briefly sonicated to dissociate cell membranes. Fifty
μg of total protein isolated from the human cell lines or
tissues were separated on 10% SDS-polyacrylamide gels at
100 V for 1 hr. Proteins were transferred to nitrocellulose
membranes at 100 V for 75 min at 4°C. Blots were then
probed overnight at 4°C with primary antibodies. The
PDF antibody was a kind gift from Carmela Giglione
and Thierry Meinnel (Centre National de la Recherche
Scientifique, Gif-sur-Yvette, France). The MAP1D antibody
was obtained from R&D Systems (Minneapolis, MN). The
total and phosphor-ERK antibodies were purchased from
Cell Signaling. The next day, blots were rinsed with 1X
TBS-tween (0.1%) and probed with anti-rabbit secondary
antibody (Jackson Immuno Research; West Grove, PA) for
1 hr at room temperature. The western blots were analyzed
using SuperSignal West Pico Chemiluminescent Substrate
(Thermo Fisher Scientific; Rockford, IL) and images
captured using the MultiImage™ Light Cabinet (Alpha
Innotech; San Leandro, CA). PDF levels were normalized
to β-actin (Cell Signaling) expression. Immunoblots were
performed in triplicate.
Toxicity assay
Hs578Bst, Hs578T, CCD-18Co, HT-29, PrEC, and PC-3
cells were plated in 96-well microplates in growth medium
at a density of 5,000 cells/well and incubated for 24 hours.
The cells were then treated for 4 days with 0–250 μM
actinonin. The CyQUANT (Life Technologies; Grand
Island, NY) cell proliferation assay was performed according
to the manufacturer’s instructions. Fluorescent readings
were taken on day 4 to determine the percentage of viable
cells. Each condition was performed with eight replicates,
and the experiments were repeated three times.
Statistical analysis
SigmaPlot v12 software (Systat Software Inc.; Chicago, IL)
was used for all statistical analyses. For all tests, a p-valuecut-off of < 0.05 was used to determine statistical signifi-
cance. For the cell lines, the PDF and MAP1D values were
related to the standard curves for the respective targets to
yield the approximate mRNA copy number/cell. These
values were then normalized to β-actin values. The data
are expressed as the average copy number ± SD for 3 rep-
licates. A t-test comparing the PDF or MAP1D mRNA
copy number in the cancer cell lines to the copy number
in their respective normal cell lines. For the cancer tissue
cDNA plates, the average Ct value for all of the non-
cancer tissue samples was set to 1. The data are expressed
as the relative fold change in each individual sample
compared to the average of these controls. A t-test was
run for PDF mRNA expression in the cancer survey
samples compared to their non-cancer controls. One-way
ANOVA on ranks was done using Dunn’s method for
multiple comparisons in the cancer stage I-III breast,
colon, and lung samples compared to their normal tissues.
A paired t-test was done to compare the effect of
actinonin on the proliferation of the cancer cell line to the
normal cell line. The data represent the percentage of
viable cells ± SD for 8 replicates. Finally, a t-test was used
to determine the effect of U0126 on the expression of
PDF and MAP1D mRNA in 3 independent replicates.
Results
PDF and MAP1D expression is elevated in human cancer
cell lines
We compared the expression of PDF and MAP1D in
four different types (breast, colon, lung, and prostate) of
cancer cell lines to non-cancer cell lines. PDF mRNA
expression was significantly higher in the HT-29 colon,
A549 lung, and PC-3 prostate cancer cell lines compared
to the CCD-18Co colon, Hs888Lu lung, and PrEC prostate
non-cancer cell lines (Figure 1). MAP1D was significantly
elevated in the PC-3 compared to PrEC cell line, but was
not significantly different in the other pairs of cell lines
(Figure 1). The Hs578Bst and Hs578T cell lines are a
normal breast and breast cancer cell line isolated from
the same patient. These cell lines did not significantly
differ in their PDF or MAP1D expression, although PDF
was slightly elevated and MAP1D was reduced. The data
suggest that PDF and MAP1D expression varies across
cell type and that they show altered expression in cancer
compared to non-cancer cells.
Actinonin inhibits the growth of both cancer and
non-cancer cell lines
The effect of the PDF inhibitor actinonin on the prolifera-
tion capacity of colon, breast, and prostate cancer and
non-cancer cell lines was measured. Actinonin inhibited
the proliferation of both cancer and non-cancer cell lines
in a concentration-dependent manner, but had greater
inhibition of cell proliferation in cancer cells compared
Figure 1 PDF and MAP1D mRNA expression varies across human
cell lines. The expression of PDF and MAP1D mRNA in normal breast
(Hs578Bst), colon (CCD-18Co), lung (Hs888Lu), and prostate (PrEC) cell
lines was compared to the expression in breast cancer (Hs578T), colon
cancer (HT29), lung cancer (A549), and prostate cancer (PC3) cell lines,
respectively. The mRNA copy numbers for PDF and MAP1D were
related to cDNA standards for these two genes and then normalized
to β-actin levels. PDF was significantly (denoted by “a”) elevated in the
colon, lung, and prostate cancer cell lines compared to their respective
normal cell lines while MAP1D was significantly (denoted by “b”)
elevated only in the prostate cancer cell line. The data represent the
average mRNA copy number for 3 replicate experiments ± SD.
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19.3, 17.3, and 113.5 μM for the Hs578T, HT-29, and
PC-3 cancer cell lines, respectively while the IC50’s
were 208, 31.9, and 207.4 μM for the Hs578Bst, CCD-18Co,
and PrEC cells, respectively. While the IC50 was higher in
the normal colon compared to the colon cancer cell line,
the difference in the percentage of viable cells was not
statistically significant. In contrast, actinonin significantly
affected the growth of breast and prostate cancer cellsFigure 2 Actinonin inhibits the growth of cancer cell lines to a greate
and breast cancer (Hs578T), (B) normal colon (CCD18Co) and colon cancer
lines were treated with 0–250 μM actinonin for 96 hrs before the percenta
actinonin was significantly greater in the breast cancer and prostate cance
represent the percentage of viable cells ± SD for 3 experiments with 8 replcompared to their non-cancer cell controls. In general,
the data suggest that inhibition of PDF by actinonin has
a greater effect on proliferation of cancer cells compared
to normal cells.
PDF mRNA is elevated in many cancer tissues
TissueScanTM Cancer qPCR Arrays containing cDNA
from 96 tissue samples representing eight different cancers
(breast, colon, kidney, liver, lung, ovary, prostate, thyroid)
were used to determine PDF expression in cancer com-
pared to non-cancer tissues. For each tissue type, the
array contained 3 normal control tissues and 9 cancer
tissues. With the exception of liver cancer that showed
no change compared to control liver samples, PDF was
at least slightly elevated in all cancer tissues compared to
control, and PDF mRNA levels were significantly elevated
in the breast, colon, and lung cancer tissue samples
compared to their non-cancer samples (Figure 3). Breast
cancer showed a 5.8-fold increase in expression of PDF
while colon and lung showed a 3.5 and 3.4-fold increase
in PDF expression, respectively.
Additional tissue panels for breast, colon, and lung
cancer patients were used to validate the previous results
and to assess MAP1D levels in these cancer types. Colon
and lung tissue panels contained 48 matched normal
and cancer tissue samples from 24 cancer patients while
the breast tissue panels contained 48 unmatched tissue
samples that included 12 normal breast tissue controls
and 36 breast cancer samples at various disease stages.
Similar to the first results, PDF was elevated in breast,
colon, and lung cancer samples and showed stage-
dependent expression with the highest expression in
late stage breast cancer, but early stage colon and lung
cancers (Figure 4A). MAP1D mRNA expression wasr degree than non-cancer cell lines. (A) Normal breast (Hs578Bst)
(HT29), and (C) normal prostate (PrEC) and prostate cancer (PC3) cell
ge of viable cells was determined. The growth-inhibitory effect of
r cell lines than in their non-cancer control cell lines. The data
icates each.
Figure 3 PDF mRNA is significantly elevated in breast, colon, and lung cancer. With the exception of liver, that showed equal expression,
PDF was elevated in all cancers (●) compared to non-cancer/normal (○) tissues. All stages of disease were pooled for the cancer groups.
Statistically significant differences (*) were observed in breast, colon, and lung cancers with expression values 5.8, 3.5, and 3.4-fold higher in
cancer compared to normal tissues, respectively.
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surprisingly reduced in breast cancer samples compared
to control samples (Figure 4B). There was no significant
change in MAP1D mRNA levels in lung cancer samples
at any stage compared to control. These results suggest
PDF and MAP1D expression is altered in certain cancer
tissues and that expression of these enzymes is correlated
with the stage of disease.Figure 4 PDF and MAP1D mRNA expression varies with stage in brea
expression is shown for normal (●) tissues relative to stage I (○), stage II (▼
PDF levels are significantly (*) elevated in late-stage breast, and early-stage
in early-stage colon cancer, but decreased in breast cancer.PDF protein levels are elevated in colon cancer tissues
To verify that the increased PDF mRNA levels translated to
increased PDF protein levels, we screened two sets of colon
cancer tissues for PDF expression. Matched colon cancer
and normal colon tissue sets were obtained from two pa-
tients at the VA Hospital in Fargo, ND in accordance with
IRB policies. Western blotting for PDF revealed a striking
elevation of PDF expression in the tumor sample of both ofst, colon, and lung cancer samples. (A) PDF and (B) MAP1D mRNA
), and stage III (Δ) tissues for breast, colon, and lung cancer patients.
colon and lung cancers while MAP1D levels are significantly increased
Figure 5 PDF protein expression is elevated in colon tumor
tissues. Western blotting was done to determine the expression of
PDF in colon cancer tissue samples (T) relative to normal colon
tissue (N) from two patients. Elevated PDF levels were found in the
colon tumor samples for each patient. A β-actin antibody was used
to confirm equal protein loading of the tissue samples for each
patient. Two replicate experiments were performed and this image
shows one representative experiment.
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tissue (Figure 5).
Inhibition of MEK/ERK results in reduced expression of
PDF and MAP1D in colon cancer cells
The regulation of PDF or MAP1D expression in human
cells has not been previously studied. To understand
potential mechanisms that regulate PDF and MAP1D
gene expression, we used pharmacological inhibitors to
target the MEK/ERK, PI3K, and mTOR signaling path-
ways and determined their effects on PDF or MAP1D
expression. Treatment of HT-29 colon cancer cells with
the MEK inhibitor U0126 resulted in a 51% reduction in
expression of PDF mRNA and a 47% reduction in MAP1D
(Figure 6A). Western blotting confirmed that U0126
inhibited ERK signalling these cells (Figure 6B). Unlike
U0126, the PI3K inhibitor LY294002 and mTOR inhibitorFigure 6 Inhibition of MEK down-regulates PDF and MAP1D mRNA ex
cells with 10 μM U for 5 hr resulted in about a 50% reduction in both PDF
that 5 hr treatment of HT-29 colon cancer cells with 10 μM U reduced pho
determined in order to show equal protein loading. (C) Treatment of HT-2
not affect PDF mRNA expression. These experiments were repeated 3 time
inhibitor-treated cells relative to the vehicle-treated controls. Statistically sigrapamycin did not have an effect on PDF expression in
HT-29 cells (Figure 6C).
Discussion
PDF and MAP are essential enzymes in prokaryotic
peptide synthesis, but their role in eukaryotic cells is
less appreciated. Previous studies have suggested PDF
and MAP1D as therapeutic targets for cancer treatment
given their roles in modulating cell proliferation, adhesion,
and aerobic respiration [11-13]. As a result, the goal of this
research was to characterize the expression pattern of PDF
and MAP1D in human cancer tissues in order to better
understand their potential roles in these cancers.
Over-expression of MAP1D has been previously observed
in colon cancer tissues; 7 out of 8 colon cancer patients
showed increased MAP1D mRNA expression and 9 out of
12 patients showed increased MAP1D protein expression
[12]. Similarly, we also found that MAP1D was elevated in
colon cancers, but not lung cancers. Interestingly we found
that MAP1D mRNA expression was significantly reduced
in breast cancer samples compared to normal breast tissue.
This is the first report to suggest PDF is over-expressed
in cancer, particularly breast, colon, and lung. Stage-
dependent expression of PDF was observed in the tissue
samples where higher expression was found in early stages
of colon and lung cancer, but later stages of breast cancer.
Early expression of PDF indicates it plays a role in the pro-
liferation of tumor cells. The over-expression of PDF and
MAP1D, particularly in early-stage colon cancer, suggests
that these enzymes are important for cancer cell growth.
PDF and MAP1D are encoded in the nuclear genome
(chromosome 16 and 2, respectively) and translocate topression in colon cancer cells. (A) Treatment of HT-29 colon cancer
and MAP1D mRNA expression. (B) Western blot analysis confirmed
sphorylated ERK (pERK) levels. Total ERK (tERK) expression was
9 cells with other inhibitors Ly294002 (LY) and rapamycin (Rap) does
s and the data represent the average relative gene expression in the
nificant (p < 0.05) differences are denoted by *.
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expression of both HsPDF and MAP1D was regulated by a
similar pathway. Use of the MEK inhibitor U0126 resulted
in about a 50% reduction in PDF and MAP1D expression
in a human colon cell line. Conversely, rapamycin and
LY294002 had little effect on PDF expression suggesting
the MEK/ERK pathway specifically contributes to the
expression of NME enzymes. A genetic and functional
linkage of PDF and MAP1D has been shown in other
animal genomes suggesting the tight regulation of NME ac-
tivity in eukaryotic mitochondria [8]. The involvement of a
growth-regulatory pathway in modulating PDF expression,
provides further support that PDF promotes the growth
of tumors and lends support to the pursuit of PDF in-
hibitors as cancer therapies.
Lee et al. showed that the PDF inhibitor actinonin se-
lectively inhibited the proliferation of numerous cancer
cell lines while having a minimal effect on the growth of
non-cancer cell lines [13]. Similarly, our data show that
actinonin had significantly greater growth-inhibitory effects
on breast and prostate cancer cells than non-cancer
cell lines. These results suggest that PDF does play a
role in the growth of cancer cells and may offer a selective
target for cancer treatment.
Conclusions
In conclusion, we found that PDF is up-regulated in several
cancer types including breast, colon, and lung. Our data
suggest that the MEK/ERK pathway contributes to the ex-
pression of PDF and MAP1D colon cancer cells. Finally, we
demonstrated that the PDF inhibitor actinonin inhibits the
growth of cancer cell lines to a greater degree than non-
cancer cell lines. These data suggest that PDF and MAP1D
may function as oncogenes to promote tumor development
and are potential selective targets for colon cancer therapy.
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